COMPASS Pathways (NASDAQ:CMPS – Get Rating) is scheduled to post its quarterly earnings results before the market opens on Tuesday, May 10th. Analysts expect COMPASS Pathways to post earnings of ($0.68) per share for the quarter.
COMPASS Pathways (NASDAQ:CMPS – Get Rating) last posted its earnings results on Thursday, February 24th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.13). During the same period in the previous year, the company posted ($0.52) EPS. On average, analysts expect COMPASS Pathways to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Shares of NASDAQ:CMPS traded down $0.49 during trading on Wednesday, reaching $9.08. The company had a trading volume of 603 shares, compared to its average volume of 257,793. The firm’s fifty day moving average is $12.55 and its 200 day moving average is $20.96. The firm has a market capitalization of $381.54 million, a PE ratio of -5.10 and a beta of 3.11. COMPASS Pathways has a twelve month low of $9.06 and a twelve month high of $49.51.
In other news, Director David Y. Norton sold 3,384 shares of the stock in a transaction on Tuesday, March 29th. The shares were sold at an average price of $12.48, for a total transaction of $42,232.32. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Ekaterina Malievskaia sold 6,372 shares of the company’s stock in a transaction on Tuesday, March 29th. The stock was sold at an average price of $12.48, for a total transaction of $79,522.56. The disclosure for this sale can be found here.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its holdings in shares of COMPASS Pathways by 1,812.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,098 shares of the company’s stock worth $69,000 after buying an additional 2,936 shares during the period. UBS Group AG boosted its holdings in shares of COMPASS Pathways by 31.7% during the 3rd quarter. UBS Group AG now owns 3,777 shares of the company’s stock worth $114,000 after buying an additional 910 shares during the period. Royal Bank of Canada boosted its holdings in shares of COMPASS Pathways by 21.3% during the 3rd quarter. Royal Bank of Canada now owns 8,066 shares of the company’s stock worth $240,000 after buying an additional 1,418 shares during the period. Geode Capital Management LLC boosted its holdings in shares of COMPASS Pathways by 34.8% during the 3rd quarter. Geode Capital Management LLC now owns 9,295 shares of the company’s stock worth $277,000 after buying an additional 2,400 shares during the period. Finally, LPL Financial LLC bought a new stake in shares of COMPASS Pathways during the 4th quarter worth $234,000. 17.86% of the stock is owned by institutional investors and hedge funds.
A number of analysts have recently weighed in on CMPS shares. Zacks Investment Research raised shares of COMPASS Pathways from a “sell” rating to a “hold” rating in a research note on Monday. Canaccord Genuity Group reduced their price target on shares of COMPASS Pathways from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Monday, February 28th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, COMPASS Pathways has an average rating of “Buy” and an average target price of $74.89.
About COMPASS Pathways (Get Rating)
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder.
Receive News & Ratings for COMPASS Pathways Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for COMPASS Pathways and related companies with MarketBeat.com’s FREE daily email newsletter.